Research Use Only · All products are strictly for in-vitro laboratory research purposes only and not for human or veterinary consumption.

GMR3RT-30Purity not reported
Click to enlarge
Metabolic & Incretin Research

GMR-3 RT

Reference analogs studied for GLP-1, GIP, glucagon and AMPK signaling in laboratory models. For in-vitro research only; not for human or animal use.

Available sizes
⇄ Compare with related compounds →

Zelle to AFFLUENT SOCIETY LLC · paid orders ship the same business day with tracking · discreet outer box · COA by batch at /verify.

After manual payment confirmation; weekends and holidays ship the next business day. Published certificates only; some lots are still awaiting documentation.

Batch certificates

Certificate forthcoming for this lot

No certificate is currently published for this size; no publication date or fulfillment lot is assigned.

Quality & Verification
Source Report
Review available COA
Quantitative Assay
When reported in COA
Identity Method
As recorded by laboratory
Reported Purity
See exact lot report
Research Dossier

The triple receptor next-generation agonist.

In plain English

GMR-3 RT takes the twincretin idea one step further: it activates three receptors — GLP-1, GIP, and glucagon — simultaneously. The addition of glucagon activity is intended to raise energy expenditure alongside the appetite and glucose effects of the other two.

Key research areas

  • Triple-agonist receptor pharmacology
  • Energy-expenditure and thermogenic signaling
  • Hepatic-fat and liver-metabolism studies
  • Comparative efficacy vs. single/dual agonists
Pathway
Metabolic & Incretin Research
Also known as
GLP-1 / GIP / Glucagon Triple Agonist (formerly Retatrutide)
How it's studied ↓

Simultaneous activation of GLP-1 and GIP amplifies incretin-driven insulin and satiety pathways, while controlled glucagon-receptor activity engages hepatic energy expenditure and lipid mobilization.

Summarizes published preclinical literature for laboratory reference only. Not a claim about human use or about our material.

3D Molecular Architecture · Sequence & Residues
Plate RETATRUTIDE
39
Residues · modified or non-standard sequence
Formula
C221H343N51O64
Molecular weight
4,731.53 g/mol
Residues
39
CAS registry
2381089-83-2

Idealized helix of the published sequence for laboratory reference; not a solved 3D structure or a claim about any lot.

Research Literature
Full Library →

Independent publications; not a claim about our material or about human use.

  1. Triple hormone receptor agonist retatrutide for obesity — a phase 2 trial
    Jastreboff AM, et al. · N Engl J Med · 2023 · PMID 37356241

Related in Metabolic & Incretin Research

Tirzepatide 30 mg research vial
Sold out

Metabolic & Incretin Research

COA ✓
Tirzepatide

$119.99